Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387901 | 1.00 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL5255020 | 1.00 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| Hydrochloric Acid SCHEMBL1003531 | 0.98 | USP2 (0.44) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL1913754 | 0.88 | HCRTR1 (0.44) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL8144693 | 0.78 | HTR2A (0.41) | USP2NPC1MEN1KMT2APOLB | |
| SCHEMBL24075123 | 0.75 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL10373039 | 0.75 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL12657420 | 0.75 | NPC1 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL7556064 | 0.75 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL12651544 | 0.75 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556878-B2 | Thiourea compounds and their use as inhibitors of Sirt2 or Sirt5 | CORNELL UNIVERSITY (US) | 2020-02-11 | — | — | US | disclosed |
| US-20160130246-A1 | THIOUREA COMPOUNDS AND THEIR USE AS INHIBITORS OF SIRT2 OR SIRT5 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-12 | — | — | US | disclosed |
| WO-2014197775-A1 | THIOUREA COMPOUNDS AND THEIR USE AS INHIBITORS OF SIRT2 OR SIRT5 | CORNELL UNIVERSITY (US) | 2014-12-11 | — | — | WO | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| WO-2000078744-A1 | THIOCHROMAN DERIVATIVES AGAINST NEUROLOGICAL DISORDERS | ASTRAZENECA UK LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0480714-A2 | HIV protease inhibitors having symmetrical structure | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | disclosed |
| US-5035739-A | PLANT GROWTH REGULATORS | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1991-07-30 | — | — | US | disclosed |
| US-4919705-A | PLANT GROWTH REGULATORS | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-04-24 | — | — | US | disclosed |
| EP-0305529-A1 | TRIFLUOROMETHANESULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING SAME | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130246-A1 | THIOUREA COMPOUNDS AND THEIR USE AS INHIBITORS OF SIRT2 OR SIRT5 | SIRT2, SIRT3, SIRT1 | USP2 1003/4885NPC1 2620/4885ALPL 4854/4885 |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | USP2 2880/4885NPC1 1738/4885ALPL 4417/4885 |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | USP2 2880/4885NPC1 1738/4885ALPL 4417/4885 |
| US-10556878-B2 | Thiourea compounds and their use as inhibitors of Sirt2 or Sirt5 | SIRT2, SIRT3, SIRT1 | USP2 1003/4885NPC1 2620/4885ALPL 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.